Prognostic effect of lncRNA SNHG7 on cancer outcome: a meta and bioinformatic analysis

BMC Cancer

Hongmei Wu¹  Shifeng Huang²  Xian Chen³  Qingwu Tian³  Yunyuan Zhang³  Qing Wang³  Qian Dong⁴ 

[1]Department of Abdominal Ultrasound, the Affiliated Hospital of Qingdao University, 266003, Qingdao, Shandong, China

[2]Department of Clinical Laboratory Medicine, the First Affiliated Hospital of Chongqing Medical University, No. 1 Friendship Road, Yuzhong District, 400016, Chongqing, China

[3]Department of Clinical Laboratory, the Affiliated Hospital of Qingdao University, 266003, Qingdao, Shandong, China

[4]Department of Pediatric Surgery, The Affiliated Hospital of Qingdao University, 266003, Qingdao, Shandong, China

[5]Shandong Key Laboratory of Digital Medicine and Computer-Assisted Surgery, 266003, Qingdao, Shandong, China

[6]Shandong College Collaborative Innovation Center of Digital Medicine Clinical Treatment and Nutrition Health, 266003, Qingdao, China

关键词: Cancer;    SNHG7;    meta-analysis;    prognostic biomarker;   

DOI  :  10.1186/s12885-021-09068-w

来源: Springer

【 摘 要 】

BackgroundNew evidence from clinical and fundamental researches suggests that SNHG7 is involved in the occurrence and development of carcinomas. And the increased levels of SNHG7 are associated with poor prognosis in various kinds of tumors. However, the small sample size was the limitation for the prognostic value of SNHG7 in clinical application. The aim of the present meta-analysis was to conduct a qualitative analysis to explore the prognostic value of SNHG7 in various cancers.MethodsArticles related to the SNHG7 as a prognostic biomarker for cancer patients, were comprehensive searched in several electronic databases. The enrolled articles were qualified via the preferred reporting items for systematic reviews and meta-analysis of observational studies in epidemiology checklists. Additionally, an online database based on The Cancer Genome Atlas (TCGA) was further used to validate our results.ResultsWe analyzed 2418 cancer patients that met the specified criteria. The present research indicated that an elevated SNHG7 expression level was significantly associated with unfavorable overall survival (OS) (HR = 2.45, 95% CI: 2.12–2.85, p <0.001). Subgroup analysis showed that high expression levels of SNHG7 were also significantly associated with unfavorable OS in digestive system cancer (HR = 2.31, 95% CI: 1.90–2.80, p <0.001) and non-digestive system cancer (HR = 2.67, 95% CI: 2.12–3.37, p <0.001). Additionally, increased SNHG7 expression was found to be associated with tumor stage and progression (III/IV vs. I/II: HR = 1.76, 95% CI: 1.57–1.98, p <0.001). Furthermore, elevated SNHG7 expression significantly predicted lymph node metastasis (LNM) (HR = 1.98, 95% CI: 1.74–2.26, p <0.001) and distant metastasis (DM) (HR = 2.49, 95% CI: 1.88–3.30, p <0.001) respectively. No significant heterogeneity was observed among these studies. SNHG7 was significantly upregulated in four cancers and the elevated expression of SNHG7 predicted shorter OS in four cancers, worse DFS in five malignancies and worse PFI in five carcinomas based on the validation using the GEPIA on-line analysis tool.ConclusionsThe present analysis suggests that elevated SNHG7 is significantly associated with unfavorable OS, tumor progression, LNM and DM in various carcinomas, and may be served as a promising biomarker to guide therapy for cancer patients.

【 授权许可】

CC BY